Results from the Phase II CheckMate 650 trial, published in Nature Communications, demonstrate that the investigational combination of immune checkpoint inhibitors ipilimumab and nivolumab achieved antitumor responses in a subset of patients with chemotherapy-resistant disease.

Using the unique capabilities of the Allison Institute’s immunotherapy platform, researchers discovered an immune signature linked with prolonged overall survival, which has the potential to help physicians identify who would be most likely to benefit from this combination.

The study was led by principal investigator Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology, vice president of Immunobiology, and director of scientific programs for the Allison Institute.